ArticleBMC infectious diseases2017
Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- The Economics of Antibiotic Resistance: A Systematic Review and Meta-analysis Based on Global Research.Applied health economics and health policy · 2026Pooled it
- Pooled it
- Pooled it
- Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.Antimicrobial resistance and infection control · 2019Pooled it
- Clinical Characteristics and Risk Factors of Carbapenem-ResistantInfection and drug resistance · 2026Article
- The Spectrum of Bacterial Infection in a Large Cohort of Chinese Pediatric Patients with Inborn Errors of Immunity: A Nine-year, Retrospective, Single-center Study.Journal of clinical immunology · 2025Article
- The prevalence and risk of mortality associated with antimicrobial resistance within nosocomial settings-a global systematic review and meta-analysis of over 20,000 patients.EClinicalMedicine · 2025Article
- Joint surveillance and correlation analysis of antimicrobial resistance and consumption of seven targeted bacteria, 2017-2023.Scientific reports · 2025Article
- Economic costing methodologies for drug-resistant bacterial infections in humans in low-and middle-income countries: a systematic review.Health economics review · 2025Review
- Prognostic Value of Procalcitonin and Procalcitonin Clearance in Septic Shock Patients: A Study from a Tertiary Teaching Hospital in Southern China.Infection and drug resistance · 2025Article
- The relationship of prescriber training level to restricted antibiotic prescribing appropriateness at a tertiary academic hospital: a retrospective study.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Clinical risk factors and outcomes of carbapenem-resistantMicrobiology spectrum · 2024Article
- Extended Spectrum β-Lactamase-Producing Enterobacterales of Shrimp and Salmon Available for Purchase by Consumers in Canada-A Risk Profile Using the Codex Framework.Antibiotics (Basel, Switzerland) · 2023Review
- The impact of COVID-19 pandemic on hand hygiene compliance of healthcare workers in a tertiary hospital in East China.Frontiers in medicine · 2023Article
- Carbapenem-resistantEpidemiology and infection · 2022Article
- Rapid Detection of Carbapenem-ResistantInfection and drug resistance · 2022Article
- In vitro Activity of Meropenem-Vaborbactam versus Other Antibiotics Against Carbapenem-ResistantInfection and drug resistance · 2021Article
- Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-ResistantInfection and drug resistance · 2021Article
- Epidemiology and molecular characteristics of the type VI secretion system in Klebsiella pneumoniae isolated from bloodstream infections.Journal of clinical laboratory analysis · 2020Article
- Developing a risk prediction model for multidrug-resistant bacterial infection in patients with biliary tract infection.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence and spread of Carbapenem-resistant Escherichia coli (CREC) is becoming a serious problem in Chinese hospitals, however, the data on this is scarce. Therefore, we investigate the risk factors for healthcare-associated CREC infection and study the incidence, antibiotic resistance and medical costs of CREC infections in our hospital.
methodsWe conducted a retrospective, matched case-control-control, parallel study in a tertiary teaching hospital. Patients admitted between January 2012 and December 2015 were included in this study. For patients with healthcare-associated CREC infection, two matched subject groups were created; one group with healthcare-associated CSEC infection and the other group without infection.
resultsMultivariate conditional logistic regression analysis demonstrated that prior hospital stay (<6 months) (OR:3.96; 95%CI:1.26-12.42), tracheostomy (OR:2.24; 95%CI: 1.14-4.38), central venous catheter insertion (OR: 8.15; 95%CI: 2.31-28.72), carbapenem exposure (OR: 12.02; 95%CI: 1.52-95.4), urinary system disease (OR: 16.69; 95%CI: 3.01-89.76), low hemoglobin (OR: 2.83; 95%CI: 1.46-5.50), and high blood glucose are associated (OR: 7.01; 95%CI: 1.89-26.02) with CREC infection. Total costs (p = 0.00), medical examination costs (p = 0.00), medical test costs (p = 0.00), total drug costs (p = 0.00) and ant-infective drug costs (p = 0.00) for the CREC group were significantly higher than those for the no infection group. Medical examination costs (p = 0.03), total drug costs (p = 0.03), and anti-infective drug costs (p = 0.01) for the CREC group were significantly higher than for the CSEC group. Mortality in CREC group was significantly higher than the CSEC group (p = 0.01) and no infection group (p = 0.01).
conclusionMany factors were discovered for acquisition of healthcare-associated CREC infection. CREC isolates were resistant to most antibiotics, and had some association with high financial burden and increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.